Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration.
Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, He L, Chen Y, Chen H, Luo W, Lu Z, Xie J, Churchill H, Xu Y, Zhou Z, Wu G, Yu C, John S, Hirayasu K, Nguyen N, Liu X, Huang F, Li L, Deng H, Tang H, Sadek AH, Zhang L, Huang T, Zou Y, Chen B, Zhu H, Arase H, Xia N, Jiang Y, Collins R, You MJ, Homsi J, Unni N, Lewis C, Chen GQ, Fu YX, Liao XC, An Z, Zheng J, Zhang N, Zhang CC. Deng M, et al. Among authors: liao xc. Nature. 2018 Oct;562(7728):605-609. doi: 10.1038/s41586-018-0615-z. Epub 2018 Oct 17. Nature. 2018. PMID: 30333625 Free PMC article.
Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development.
Gui X, Deng M, Song H, Chen Y, Xie J, Li Z, He L, Huang F, Xu Y, Anami Y, Yu H, Yu C, Li L, Yuan Z, Xu X, Wang Q, Chai Y, Huang T, Shi Y, Tsuchikama K, Liao XC, Xia N, Gao GF, Zhang N, Zhang CC, An Z. Gui X, et al. Among authors: liao xc. Cancer Immunol Res. 2019 Aug;7(8):1244-1257. doi: 10.1158/2326-6066.CIR-19-0036. Epub 2019 Jun 18. Cancer Immunol Res. 2019. PMID: 31213474 Free PMC article.
Blocking LAIR1 signaling in immune cells inhibits tumor development.
Xie J, Gui X, Deng M, Chen H, Chen Y, Liu X, Ku Z, Tan L, Huang R, He Y, Zhang B, Lewis C, Chen K, Xu L, Xu J, Huang T, Liao XC, Zhang N, An Z, Zhang CC. Xie J, et al. Among authors: liao xc. Front Immunol. 2022 Sep 21;13:996026. doi: 10.3389/fimmu.2022.996026. eCollection 2022. Front Immunol. 2022. PMID: 36211388 Free PMC article.
Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors.
Taylor MH, Naing A, Powderly J, Woodard P, Chung L, Lin WH, Tian H, Siemers N, Xiang H, Deng R, Hong K, Valencia D, Huang T, Zhu Y, Liao XC, Schebye XM, Patel MR. Taylor MH, et al. Among authors: liao xc. J Immunother Cancer. 2024 Nov 20;12(11):e010006. doi: 10.1136/jitc-2024-010006. J Immunother Cancer. 2024. PMID: 39567210 Free PMC article. Clinical Trial.
[A Family with Congenital Dysfibrinogenemia and Blood Transfusion].
Liao XC, Zhang SS, Yang ZJ, Zhu CL, Huang HN, Luo RX, Li SN, Xie HQ, Li HL, Mo ZN. Liao XC, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Oct;31(5):1469-1474. doi: 10.19746/j.cnki.issn.1009-2137.2023.05.034. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023. PMID: 37846702 Chinese.
[Gene Sequencing Analyses of 10 ABO Ambiguous Blood Group Samples].
Huang HN, Mo ZN, Liao XC, Yang ZJ, Wei YR, Zhu CL, Li HL. Huang HN, et al. Among authors: liao xc. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Aug;30(4):1193-1197. doi: 10.19746/j.cnki.issn.1009-2137.2022.04.034. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022. PMID: 35981383 Chinese.
53 results